

RSV Vaccine and mAb Snapshot

TARGET INDICATION: P=PEDIATRIC M=MATERNAL E=ELDERLY

	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	MARKET APPROVED
LIVE-ATTENUATED/ CHIMERIC	LID/NIAID/NIH PIV1-3/RSV LID/NIAID/NIH RSV	Blue Lake PIV5/RSV Codagenix, LID/NIAID/NIH RSV Intravacc RSV-ΔG Pontificia Universidad Catolica de Chile BCG/RSV SIPL, St. Jude Hospital SeV/RSV	Meissa Vaccines RSV Sanofi, LID/NIAID/NIH RSV		
PROTEIN-BASED • INACTIVATED • PARTICLE • SUBUNIT	Blue Willow Biologics Inactivated RSV Georgia State University VLP Health Guard RSV F Protein Sanofi Replaced by RNA Nanoparticle candidate Sciogen RSV G Protein University of Georgia RSV G Protein University of Massachusetts VLP University of Saskatchewan RSV F Protein	Icosavax RSV/hMPV VLP Immunovaccine, VIB RSV SH Protein NIH/NIAID/VRC RSV F Protein Virometix VLP	Advaccine Biotechnology RSV G Protein Daiichi Sankyo Protein ?	GlaxoSmithKline RSV F Protein Discontinued Pfizer RSV F Protein Pfizer RSV F Protein	
NUCLEIC ACID	CureVac RNA	Moderna RNA Sanofi RNA		Moderna RNA	
RECOMBINANT VECTORS	BravoVax Adenovirus GlaxoSmithKline Adenovirus Vaxart Adenovirus		Janssen Pharmaceutical Adenovirus	Bavarian Nordic MVA Janssen Pharmaceutical Adenovirus	
IMMUNO-PROPHYLAXIS	Aridis Anti-F mAb Pontificia Universidad Catolica de Chile Anti-N mAb UCAB, mAbXience Anti-F mAb	Gates MRI Anti-F mAb Trinomab Biotechnology Anti-F mAb		Merck Anti-F mAb	Astra Zeneca, Sanofi Nirsevimab Astra Zeneca Palivizumab

UPDATED: January 3, 2023

Indicates Change

<https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/>